

## MOLECULAR CANCER THERAPEUTICS

## TABLE OF CONTENTS

## HIGHLIGHTS

1383 Selected Articles from This Issue

## SMALL MOLECULE THERAPEUTICS

1385 **MMAE Delivery Using the *Bicycle* Toxin Conjugate BT5528**

**A C** Gavin Bennett, Amy Brown, Gemma Mudd, Philip Huxley, Katerine Van Rietschoten, Silvia Pavan, Lihong Chen, Sophie Watcham, Johanna Lahdenranta, and Nicholas Keen

1395 **The Dysregulated Pharmacology of Clinically Relevant *ESR1* Mutants is Normalized by Ligand-activated WT Receptor**

**A C** Kaitlyn J. Andreano, Jennifer G. Baker, Sunghee Park, Rachid Safi, Sandeep Artham, Steffi Oesterreich, Rinath Jeselsohn, Myles Brown, Sarah Sammons, Suzanne E. Wardell, Ching-yi Chang, John D. Norris, and Donald P. McDonnell

1406 **Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734**

Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic, Kara M. Soroko, Benjamin K. Eschle, Margaret K. Wilkens, Prafulla C. Gokhale, Francis Giles, Andrew Griffin, Bill Brown, Geoffrey I. Shapiro, Beth E. Zucconi, Philip A. Cole, Madeleine E. Lemieux, and Christopher A. French

1415 **Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma**

Shiva Kant, Pravin Kesarwani, Anthony R. Guastella, Praveen Kumar, Stewart F. Graham, Katie L. Buelow, Ichiro Nakano, and Prakash Chinnaiyan

1423 **A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer**

**A C** Charlotte K. Milton, Annette J. Self, Paul A. Clarke, Udai Banerji, Federica Piccioni, David E. Root, and Steven R. Whittaker

1436 **Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor**

**A C** Remi Adelaiye-Ogala, Berkley E. Gryder, Yen Thi Minh Nguyen, Aian Neil Alilin, Adlai R. Grayson, Wardah Bajwa, Keith H. Jansson, Michael L. Beshiri, Supreet Agarwal, Jose Antonio Rodriguez-Nieves, Brian Capaldo, Kathleen Kelly, and David J. VanderWeele

1448 **Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma**

Gireesh B. Reddy, David L. Kerr, Ivan Spasojevic, Artak Tovmasyan, David Hsu, Brian E. Brigman, Jason A. Somarelli, David Needham, and William C. Eward

1462 **Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch**

Erik T. Goka, Pallavi Chaturvedi, Dayrelis T. Mesa Lopez, and Marc E. Lippman

## LARGE MOLECULE THERAPEUTICS

1474 **Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3**

Alexander Rau, Wolfgang S. Lieb, Oliver Seifert, Jonas Honer, Dennis Birnstock, Fabian Richter, Nadine Aschmoneit, Monilola A. Olayioye, and Roland E. Kontermann

## COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1486 **Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors**

**A C** Andrew A. Davis, Wade T. Iams, David Chan, Michael S. Oh, Robert W. Lentz, Neil Peterman, Alex Robertson, Abhik Shah, Rohith Srivas, Timothy J. Wilson, Nicole J. Lambert, Peter S. George, Becky Wong, Haleigh W. Wood, Jason C. Close, Ayse Tezcan, Ken Nesmith, Haluk Tezcan, and Young Kwang Chae

# TABLE OF CONTENTS

**1497 A Qualitative Transcriptional Signature for Predicting Prognosis and Response to Bevacizumab in Metastatic Colorectal Cancer**

Jing Yang, Kai Song, Wenbing Guo, Hailong Zheng, Yelin Fu, Tianyi You, Kai Wang, Lishuang Qi, Wenyan Zhao, and Zheng Guo

**1530 A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma**

Marina Li, Cindy Lin, Hui Deng, Joann Strnad, Luca Bernabei, Dan T. Vogl, James J. Burke, and Yulia Nefedova

## CANCER BIOLOGY AND TRANSLATIONAL STUDIES

**1506 Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids**

Mégane Vernon, Bernard Lambert, Matthieu Meryet-Figuière, Emilie Brotin, Louis-Bastien Weiswald, Hippolyte Paysant, Nicolas Vigneron, Anaïs Wambecke, Edwige Abeilard, Florence Giffard, Marie-Hélène Louis, Cécile Blanc-Fournier, Pascal Gauduchon, Laurent Poulain, and Christophe Denoyelle

**1520 EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth**

Sameer H. Issaq, Arnulfo Mendoza, Ria Kidner, Tracy I. Rosales, Damien Y. Duveau, Christine M. Heske, Jason M. Rohde, Matthew B. Boxer, Craig J. Thomas, Ralph J. DeBerardinis, and Lee J. Helman

**1539 DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization**

**A C** Parthasarathy Chandrakesan, Janani Panneerselvam, Randal May, Nathaniel Weygant, Dongfeng Qu, William R. Berry, Kamille Pitts, Ben Z. Stanger, Chinthalapally V. Rao, Michael S. Bronze, and Courtney W. Houchen

**1550 Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis**

Lanxin Luo, Xiudong Guan, Gulnaz Begum, Dawei Ding, Jenesis Gayden, Md Nabiul Hasan, Victoria M. Fiesler, Jacob Dodelson, Gary Kohanbash, Baoli Hu, Nduka M. Amankulor, Wang Jia, Maria G. Castro, Baoshan Sun, and Dandan Sun

**1562 Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer**


Hiroki Izumi, Zhiyong Wang, Yusuke Goto, Toshinori Ando, Xingyu Wu, Xuefeng Zhang, Hua Li, Daniel E. Johnson, Jennifer R. Grandis, and J. Silvio Gutkind

**A C** AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

In this month's edition, Bennett and colleagues disclose BT5528, a Bicycle toxin-conjugate targeting EphA2. On the cover, BT5528 is shown bound to EphA2 on the surface of HT1080 fibrosarcoma cells in a High Content Screening assay. BT5528 provided persistent toxins to tumor cells while avoiding systemic exposure and has entered a Phase I clinical trial (NCT04180371). Read the First Disclosure on page 1385.



# Molecular Cancer Therapeutics

**19 (7)**

*Mol Cancer Ther* 2020;19:1383-1571.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/19/7>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/19/7>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.